Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
gp100 Melanoma Peptide Vaccine with High-Dose IL-2 in Metastatic Melanoma
NCT00003568Phase 2Completed
- Sponsor
- University of Illinois Chicago
- Start
- Nov 1998
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of gp100:209-217 in melanoma, sponsored by University of Illinois Chicago. Started Nov 1998; status: completed.
02
Drugs
gp100:209-217
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00003568.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003568.